Jochen Senges

Jochen Senges

Auto-generated profile, based on publicly available information

Jochen Senges

Institut für Herzinfarktforschung, Bremser Strasse 79, 67063, Ludwigshafen, Germany.

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2016 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
FGfor the EARLY Registry Group
for the EARLY Registry Group
AGAnselm K. Gitt
Anselm K. Gitt
PBPeter Bramlage
Peter Bramlage
SPSebastian A. Potthoff
Sebastian A. Potthoff
PBPeter Baumgart
Peter Baumgart
RSRoland E. Schmieder
Roland E. Schmieder
Azilsartan medoxomil (AZL-M), has been demonstrated to be more effective than the other sartans currently in use; however, there is insufficient information available comparing it with ACE-inhibitors. Therefore, we aimed to compare the efficacy, safety, and tolerability of AZL-M with that of ACE-inhibitors in a real life clinical setting. The EARLY registry is a prospective, observational, national, multicentre registry with a follow-up period of 12 months. There were two principal objectives: 1) documentation of the achievement of target BP values set according to recent national and international guidelines, and 2) description of the safety profile of AZL-M. A total of 3 849 patients with essential arterial hypertension were recruited from primary care offices in Germany. Patients who initiated monotherapy at baseline comprising either AZL-M or an ACE-inhibitor were included at a ratio of seven to three. Results demonstrated that a blood pressure target of <140/90 mmHg was achieved by a significantly greater proportion of patients in the AZL-M group (61.1 %) compared with the ACE-inhibitor group (56.4 %; p < 0.05; OR, 1.21; 95 % CI, 1.03–1.42), with this finding maintained after adjusting for differences in baseline characteristics. AZL-M appeared to have an equivalent safety profile to the ACE-inhibitors, with a similar incidence of adverse events in the two patient groups (p = 0.73). These data add to the results of previous randomized controlled clinical trials suggesting that, compared with other agents that target the renin–angiotensin system, AZL-M provides statistically significant albeit small improvements in blood pressure control.